

## Chromosome Genome Mapping (CGM)

Date: October 31, 2025

---

Effective Date: November 5, 2025

This memo serves as guidance for the upcoming limited trial for the CGM assay (Chromosome Genome Mapping) based on Optical Genome Mapping (OGM) technology for a targeted group of providers from the Reproductive Genetics team. A trial will begin on November 5, 2025 for 20–30 patient samples with the clinical indication of recurrent pregnancy loss.

Collect 5-7 ml peripheral blood specimen in lavender top (EDTA) and green top (Sodium heparin) tubes. Providers should use the attached requisition form listing CGM as a test option. Each sample must be accompanied by a completed requisition and consent; incomplete submissions will not be processed. Specimens should be stored and transported at ambient temperature. The lab will receive specimens, perform testing and submit results through eRecord (under MACGM test code).

Expected turnaround times for reports is 14-28 days.

Once this target is met, the lab will notify the participating providers that a pause in testing will occur while the lab works to structure a more permanent testing workflow.

For any questions, please contact:

M. Anwar Iqbal, Ph.D., FFACMGG  
Professor  
Director, DNA Microarray CGH Laboratory  
Department of Pathology and Laboratory Medicine  
URMC Central Laboratory  
585-758-0422 Office

Christine Reilingh CG(ASCP)<sup>CM</sup>  
Supervisor, Cytogenetics Laboratory  
Department of Pathology and Laboratory Medicine  
URMC Central Laboratory, Bailey Rd.  
585.275.1075